Anti-interferon alpha treatment in SLE

Clinical Immunology

Volumn 148, Issue 3, 2013, Pages 303-312

  Kirou, Kyriakos A ^a   Gkrouzman, Elena ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Clinical trial; Interferon alpha; Plasmacytoid dendritic cells; Systemic lupus erythematosus

Indexed keywords

AGS 009; CPG 52364; CYTOKINE; DV 1179; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMO 8400; INTERFERON ALPHA KINOID; INTERFERON REGULATORY FACTOR 7; MEDI 546; MYELOID DIFFERENTIATION FACTOR 88; NEOVACS; NUCLEIC ACID; PEGINTERFERON ALPHA; PLACEBO; PREDNISONE; RONTALIZUMAB; SIFALIMUMAB; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CYTOKINE RELEASE; DIFFERENTIATION; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DRUG SAFETY; GENE TARGETING; GENETIC RISK; HELPER CELL; HUMAN; IMMUNIZATION; IMMUNOPATHOGENESIS; INTERFERON PRODUCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; VIRUS INFECTION;

ADVERSE EVENT(S); AE; ANA; ANTINUCLEAR ANTIBODIES; APECED; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; B-CELL ACTIVATION FACTOR; BAFF; BDCA2; BILAG INDEX; BLOOD DC ANTIGEN 2; BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX; CCL2; CHEMOKINE (C-C) MOTIF LIGAND 2; CHEMOKINE (C-X-C) MOTIF LIGAND 10; CLINICAL TRIAL; CXCL10; DC; DENDRITIC CELL; DEOXYRIBONUCLEASE I; DNASEI; DOUBLE STRANDED DNA; DSDNA; FC GAMMA RECEPTOR IIA, GC, GLUCOCORTICOIDS; FCΓRIIA; GLUCOCORTICOID RECEPTOR-INTERACTING PROTEIN 1; GMCSF; GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR; GRIP1; IFNΑ; IFNΑ KINOID; IFNΑ RECEPTOR; IFNΑ-K; IFN-I; IFN-REGULATED GENES; IFN-REGULATORY FACTOR; IFN-STIMULATED RESPONSE ELEMENT; IFNAR; IG; IG-LIKE TRANSCRIPT 7; IL; ILT7; IMMUNOGLOBULIN; INTERFERON ALPHA; INTERLEUKIN; INTERLEUKIN RECEPTOR ASSOCIATED KINASE; INTRAVENOUSLY; IRAK; IRF; IRG; ISRE; IV; KEYHOLE LIMPET HAEMOCYANIN; KLH; MAB; MAJOR HISTOCOMPATIBILITY COMPLEX; MHC; MONOCLONAL ANTIBODIES; MYD88; MYELOID DIFFERENTIATION FACTOR 88; NATURAL KILLER; NET; NEUTROPHIL EXTRACELLULAR TRAP; NFΚB; NK; NUCLEAR FACTOR KAPPA B; ODN; OLIGODEOXYNUCLEOTIDES; PBMC; PD; PDC; PERIPHERAL BLOOD MONONUCLEAR CELLS; PHARMACODYNAMIC; PHOSPHATIDYLINOSITOL-3 KINASE Δ; PI3KΔ; PLASMACYTOID DENDRITIC CELL; PLASMACYTOID DENDRITIC CELLS; RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED; RBP; RDBPC; REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION; RNA BINDING PROTEINS; RT-QPCR; SAE; SC; SERIOUS ADVERSE EVENT (S); SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; SLE; SLE RESPONSE INDEX; SRI; STAT; SUBCUTANEOUSLY; SYSTEMIC LUPUS ERYTHEMATOSUS; T HELPER 1; TH1; TLR; TNF ALPHA-INDUCED PROTEIN 3; TNFAIP3; TNIP1; TOLL-LIKE RECEPTORS; TRAF; TUMOR NECROSIS FACTOR Α-INDUCED PROTEIN 3-INTERACTING PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED FACTOR; TYK2; TYPE I INTERFERON(S); TYROSINE KINASE 2; ULTRAVIOLET; UV;

ANIMALS; DENDRITIC CELLS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION;

EID: 84881097754     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.02.013     Document Type: Review

References (81)

1. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 1979, 301:5-8.
2. Ronnblom L.E., Alm G.V., Oberg K.E. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 1990, 227:207-210.
3. Wilson L.E., Widman D., Dikman S.H., Gorevic P.D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin. Arthritis Rheum. 2002, 32:163-173.
4. Kirou K.A., Mavragani C.P., Crow M.K. Activation of type I interferon in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 2007, 3:579-588.
5. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202:8-32.
6. Reizis B., Colonna M., Trinchieri G., Barrat F., Gilliet M. Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system?. Nat. Rev. Immunol. 2011, 11:558-565.
7. Gregorio J., Meller S., Conrad C., Di Nardo A., Homey B., Lauerma A., Arai N., Gallo R.L., Digiovanni J., Gilliet M. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J. Exp. Med. 2010, 207:2921-2930.
8. Guiducci C., Tripodo C., Gong M., Sangaletti S., Colombo M.P., Coffman R.L., Barrat F.J. Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. J. Exp. Med. 2010, 207:2931-2942.
9. Ronnblom L., Alm G.V., Eloranta M.L. The type I interferon system in the development of lupus. Semin. Immunol. 2011, 23:113-121.
10. Vallin H., Blomberg S., Alm G.V., Cederblad B., Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 1999, 115:196-202.
11. Vallin H., Perers A., Alm G.V., Ronnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J. Immunol. 1999, 163:6306-6313.
12. Kim W.U., Sreih A., Bucala R. Toll-like receptors in systemic lupus erythematosus; prospects for therapeutic intervention. Autoimmun. Rev. 2009, 8:204-208.
13. Bave U., Magnusson M., Eloranta M.L., Perers A., Alm G.V., Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J. Immunol. 2003, 171:3296-3302.
14. Lood C., Gullstrand B., Truedsson L., Olin A.I., Alm G.V., Ronnblom L., Sturfelt G., Eloranta M.L., Bengtsson A.A. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum. 2009, 60:3081-3090.
15. Duffau P., Seneschal J., Nicco C., Richez C., Lazaro E., Douchet I., Bordes C., Viallard J.F., Goulvestre C., Pellegrin J.L., Weil B., Moreau J.F., Batteux F., Blanco P. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med 2010, 2:47ra63.
16. Weckerle C.E., Franek B.S., Kelly J.A., Kumabe M., Mikolaitis R.A., Green S.L., Utset T.O., Jolly M., James J.A., Harley J.B., Niewold T.B. Network analysis of associations between serum interferon-alpha activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011, 63:1044-1053.
17. Kirou K.A., Lee C., George S., Louca K., Peterson M.G., Crow M.K. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005, 52:1491-1503.
18. Knight J.S., Kaplan M.J. Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis. Curr. Opin. Rheumatol. 2012, 24:441-450.
19. Hakkim A., Furnrohr B.G., Amann K., Laube B., Abed U.A., Brinkmann V., Herrmann M., Voll R.E., Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:9813-9818.
20. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., Punaro M., Baisch J., Guiducci C., Coffman R.L., Barrat F.J., Banchereau J., Pascual V. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20.
21. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V., Bassett R., Amuro H., Fukuhara S., Ito T., Liu Y.J., Gilliet M. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011, 3:73ra19.
22. Niewold T.B., Hua J., Lehman T.J., Harley J.B., Crow M.K. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007, 8:492-502.
23. Niewold T.B., Kelly J.A., Flesch M.H., Espinoza L.R., Harley J.B., Crow M.K. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58:2481-2487.
24. Salloum R., Franek B.S., Kariuki S.N., Rhee L., Mikolaitis R.A., Jolly M., Utset T.O., Niewold T.B. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010, 62:553-561.
25. Musone S.L., Taylor K.E., Lu T.T., Nititham J., Ferreira R.C., Ortmann W., Shifrin N., Petri M.A., Kamboh M.I., Manzi S., Seldin M.F., Gregersen P.K., Behrens T.W., Ma A., Kwok P.Y., Criswell L.A. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat. Genet. 2008, 40:1062-1064.
26. Jacob C.O., Zhu J., Armstrong D.L., Yan M., Han J., Zhou X.J., Thomas J.A., Reiff A., Myones B.L., Ojwang J.O., Kaufman K.M., Klein-Gitelman M., McCurdy D., Wagner-Weiner L., Silverman E., Ziegler J., Kelly J.A., Merrill J.T., Harley J.B., Ramsey-Goldman R., Vila L.M., Bae S.C., Vyse T.J., Gilkeson G.S., Gaffney P.M., Moser K.L., Langefeld C.D., Zidovetzki R., Mohan C. Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6256-6261.
27. Abelson A.K., Delgado-Vega A.M., Kozyrev S.V., Sanchez E., Velazquez-Cruz R., Eriksson N., Wojcik J., Linga Reddy M.V., Lima G., D'Alfonso S., Migliaresi S., Baca V., Orozco L., Witte T., Ortego-Centeno N., Abderrahim H., Pons-Estel B.A., Gutierrez C., Suarez A., Gonzalez-Escribano M.F., Martin J., Alarcon-Riquelme M.E. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann. Rheum. Dis. 2009, 68:1746-1753.
28. Kariuki S.N., Kirou K.A., MacDermott E.J., Barillas-Arias L., Crow M.K., Niewold T.B. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J. Immunol. 2009, 182:34-38.
29. Kariuki S.N., Moore J.G., Kirou K.A., Crow M.K., Utset T.O., Niewold T.B. Age- and gender-specific modulation of serum osteopontin and interferon-alpha by osteopontin genotype in systemic lupus erythematosus. Genes Immun. 2009, 10:487-494.
30. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2610-2615.
31. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 2003, 197:711-723.
32. Crow M.K., Kirou K.A., Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity 2003, 36:481-490.
33. Kirou K.A., Lee C., George S., Louca K., Papagiannis I.G., Peterson M.G., Ly N., Woodward R.N., Fry K.E., Lau A.Y., Prentice J.G., Wohlgemuth J.G., Crow M.K. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004, 50:3958-3967.
34. Dall'era M.C., Cardarelli P.M., Preston B.T., Witte A., Davis J.C. Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 2005, 64:1692-1697.
35. Landolt-Marticorena C., Bonventi G., Lubovich A., Ferguson C., Unnithan T., Su J., Gladman D.D., Urowitz M., Fortin P.R., Wither J. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 2009, 68:1440-1446.
36. Petri M., Singh S., Tesfasyone H., Dedrick R., Fry K., Lal P., Williams G., Bauer J., Gregersen P., Behrens T., Baechler E. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 2009, 18:980-989.
37. Bauer J.W., Petri M., Batliwalla F.M., Koeuth T., Wilson J., Slattery C., Panoskaltsis-Mortari A., Gregersen P.K., Behrens T.W., Baechler E.C. Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009, 60:3098-3107.
38. T. Rose, A. Grutzkau, H. Hirseland, D. Huscher, C. Dahnrich, A Dzionek, T. Ozimkowski, W. Schlumberger, P. Enghard, A. Radbruch, G. Riemekasten, G.R. Burmester, F. Hiepe, R. Biesen, IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus, Ann. Rheum. Dis. (in press), [Published Online First: 31 October 2012]. http://dx.doi.org/10.1136/annrheumdis-2012-201586.
39. Ho V., McLean A., Terry S. Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C. J. Clin. Rheumatol. 2008, 14:166-168.
40. Nacionales D.C., Kelly-Scumpia K.M., Lee P.Y., Weinstein J.S., Lyons R., Sobel E., Satoh M., Reeves W.H. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007, 56:3770-3783.
41. Fairhurst A.M., Mathian A., Connolly J.E., Wang A., Gray H.F., George T.A., Boudreaux C.D., Zhou X.J., Li Q.Z., Koutouzov S., Banchereau J., Wakeland E.K. Systemic IFN-alpha drives kidney nephritis in B6.Sle123 mice. Eur. J. Immunol. 2008, 38:1948-1960.
42. Santiago-Raber M.L., Baccala R., Haraldsson K.M., Choubey D., Stewart T.A., Kono D.H., Theofilopoulos A.N. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 2003, 197:777-788.
43. Triantafyllopoulou A., Franzke C.W., Seshan S.V., Perino G., Kalliolias G.D., Ramanujam M., van Rooijen N., Davidson A., Ivashkiv L.B. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:3012-3017.
44. Blomberg S., Eloranta M.L., Cederblad B., Nordlin K., Alm G.V., Ronnblom L. Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus. Lupus 2001, 10:484-490.
45. Farkas L., Beiske K., Lund-Johansen F., Brandtzaeg P., Jahnsen F.L. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 2001, 159:237-243.
46. Tucci M., Quatraro C., Lombardi L., Pellegrino C., Dammacco F., Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008, 58:251-262.
47. Barrat F.J., Meeker T., Chan J.H., Guiducci C., Coffman R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007, 37:3582-3586.
48. Kirou K.A., Vakkalanka R.K., Butler M.J., Crow M.K. Induction of Fas ligand-mediated apoptosis by interferon-alpha. Clin. Immunol. 2000, 95:218-226.
49. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
50. Cucak H., Yrlid U., Reizis B., Kalinke U., Johansson-Lindbom B. Type I interferon signaling in dendritic cells stimulates the development of lymph-node-resident T follicular helper cells. Immunity 2009, 31:491-501.
51. Le Bon A., Thompson C., Kamphuis E., Durand V., Rossmann C., Kalinke U., Tough D.F. Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J. Immunol. 2006, 176:2074-2078.
52. Le Buanec H., Gougeon M.L., Mathian A., Lebon P., Dupont J.M., Peltre G., Hemon P., Schmid M., Bizzini B., Kunding T., Burny A., Bensussan A., Amoura Z., Gallo R.C., Zagury D. IFN-alpha and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18995-19000.
53. Yan B., Ye S., Chen G., Kuang M., Shen N., Chen S. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum. 2008, 58:801-812.
54. Somers E.C., Zhao W., Lewis E.E., Wang L., Wing J.J., Sundaram B., Kazerooni E.A., McCune W.J., Kaplan M.J. Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One 2012, 7:e37000.
55. Thacker S.G., Berthier C.C., Mattinzoli D., Rastaldi M.P., Kretzler M., Kaplan M.J. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J. Immunol. 2010, 185:4457-4469.
56. Reily M.M., Pantoja C., Hu X., Chinenov Y., Rogatsky I. The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J. 2006, 25:108-117.
57. Chinenov Y., Gupte R., Dobrovolna J., Flammer J.R., Liu B., Michelassi F.E., Rogatsky I. Role of transcriptional coregulator GRIP1 in the anti-inflammatory actions of glucocorticoids. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:11776-11781.
58. Guiducci C., Gong M., Xu Z., Gill M., Chaussabel D., Meeker T., Chan J.H., Wright T., Punaro M., Bolland S., Soumelis V., Banchereau J., Coffman R.L., Pascual V., Barrat F.J. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010, 465:937-941.
59. Shodell M., Shah K., Siegal F.P. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus 2003, 12:222-230.
60. Sacre K., Criswell L.A., McCune J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 2012, 14:R155.
61. Cao W., Manicassamy S., Tang H., Kasturi S.P., Pirani A., Murthy N., Pulendran B. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat. Immunol. 2008, 9:1157-1164.
62. Naranjo-Gomez M., Climent N., Cos J., Oliva H., Bofill M., Gatell J.M., Gallart T., Pujol-Borrell R., Borras F.E. Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion. Immunology 2006, 119:488-498.
63. Tajima K., Amakawa R., Ito T., Miyaji M., Takebayashi M., Fukuhara S. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 2003, 108:321-328.
64. Morimoto A.M., Flesher D.T., Yang J., Wolslegel K., Wang X., Brady A., Abbas A.R., Quarmby V., Wakshull E., Richardson B., Townsend M.J., Behrens T.W. Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2011, 63:2407-2415.
65. von Wussow P., Jakschies D., Hartung K., Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol. Int. 1988, 8:225-230.
66. Kisand K., Link M., Wolff A.S., Meager A., Tserel L., Org T., Murumagi A., Uibo R., Willcox N., Trebusak Podkrajsek K., Battelino T., Lobell A., Kampe O., Lima K., Meloni A., Ergun-Longmire B., Maclaren N.K., Perheentupa J., Krohn K.J., Scott H.S., Husebye E.S., Peterson P. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. Blood 2008, 112:2657-2666.
67. McBride J.M., Jiang J., Abbas A.R., Morimoto A., Li J., Maciuca R., Townsend M., Wallace D.J., Kennedy W.P., Drappa J. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012, 64:3666-3676.
68. Kalunian K., Merrill J.T., Maciuca R., Ouyang W.J., McBride J.M., Townsend M.J., Park E., Li J., Wei X., Morimoto A., Boismenu R., Davis J.C., Kennedy W.P. Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study. Arthritis Rheum. 2012, 64. (S1111-S1111).
69. Merrill J.T., Wallace D.J., Petri M., Kirou K.A., Yao Y., White W.I., Robbie G., Levin R., Berney S.M., Chindalore V., Olsen N., Richman L., Le C., Jallal B., White B. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann. Rheum. Dis. 2011, 70:1905-1913.
70. Yao Y., Richman L., Higgs B.W., Morehouse C.A., de los Reyes M., Brohawn P., Zhang J., White B., Coyle A.J., Kiener P.A., Jallal B. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009, 60:1785-1796.
71. Merrill J., Chindalore V., Box J., Rothfield N., Fiechtner J., Sun J., Ethgen D. Results of a randomized, placebo-controlled, phase 2A study of sifalimumab, an anti-interferon-alpha monoclonal antibody, administered subcutaneously in subjects with systemic lupus erythematosus. Ann. Rheum. Dis. 2011, 70:314.
72. Tcherepanova I., Curtis M., Sale M., Miesowicz F., Nicolette C. Results of a randomized placebo controlled phase 1a study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus. Ann. Rheum. Dis. 2012, 71:536.
73. Zagury D., Le Buanec H., Mathian A., Larcier P., Burnett R., Amoura Z., Emilie D., Peltre G., Bensussan A., Bizzini B., Gallo R.C., Koutouzov S. IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5294-5299.
74. Mathian A., Amoura Z., Adam E., Colaone F., Hoekman M.F., Dhellin O., Vandepapeliere P., Haroche J., Piette J.C., Lebon P., Grouard-Vogel G. Active immunisation of human interferon alpha transgenic mice with a human interferon alpha Kinoid induces antibodies that neutralise interferon alpha in sera from patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2011, 70:1138-1143.
75. Lauwerys B.R., Hachulla E., Spertini F., Lazaro E., Jorgensen C., Mariette X., Haelterman E., Grouard-Vogel G., Fanget B., Dhellin O., Vandepapeliere P., Houssiau F.A. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013, 65:447-456.
76. Hua J., Kirou K., Lee C., Crow M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006, 54:1906-1916.
77. Zhu F.G., Jiang W.W., Dong Y., Kandimalla E., La Monica N., Agrawal S. IMO-8400, a novel TLR7, TLR8 and TLR9 antagonist, inhibits disease development in lupus-prone NZBW/F1 mice. J. Immunol. 2012, 188.
78. Lipford G., Forsbach A., Zepp C., Nguyen T., Weeratna R., McCluskie M., Vollmer J., Davis H., Krieg A.M. Selective Toll-like receptor 7/8/9 anatgonists for the oral treatment of autoimmune diseases. American College of Rheumatology 2007 Annual Scientific Meeting 2007.
79. Guiducci C., Ghirelli C., Marloie-Provost M.A., Matray T., Coffman R.L., Liu Y.J., Barrat F.J., Soumelis V. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J. Exp. Med. 2008, 205:315-322.
80. Chiang E.Y., Yu X., Grogan J.L. Immune complex-mediated cell activation from systemic lupus erythematosus and rheumatoid arthritis patients elaborate different requirements for IRAK1/4 kinase activity across human cell types. J. Immunol. 2011, 186:1279-1288.
81. von Bernuth H., Picard C., Jin Z., Pankla R., Xiao H., Ku C.L., Chrabieh M., Mustapha I.B., Ghandil P., Camcioglu Y., Vasconcelos J., Sirvent N., Guedes M., Vitor A.B., Herrero-Mata M.J., Arostegui J.I., Rodrigo C., Alsina L., Ruiz-Ortiz E., Juan M., Fortuny C., Yague J., Anton J., Pascal M., Chang H.H., Janniere L., Rose Y., Garty B.Z., Chapel H., Issekutz A., Marodi L., Rodriguez-Gallego C., Banchereau J., Abel L., Li X., Chaussabel D., Puel A., Casanova J.L. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008, 321:691-696.